Avacta Group Plc (AVCT.L)
- Previous Close
48.00 - Open
48.00 - Bid 46.50 x --
- Ask 47.50 x --
- Day's Range
45.50 - 48.00 - 52 Week Range
45.50 - 166.98 - Volume
2,123,941 - Avg. Volume
2,974,597 - Market Cap (intraday)
166.318M - Beta (5Y Monthly) 1.20
- PE Ratio (TTM)
-- - EPS (TTM)
-0.16 - Earnings Date Apr 23, 2024 - Apr 29, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
92.33
Avacta Group Plc develops cancer therapies and diagnostics in the United Kingdom, France, North America, South Korea, and rest of Asia and Europe. The company operates through Diagnostics and Therapeutics segments. It develops products based on its proprietary Affimer and pre|CISION technology platforms. The company develops AVA6000, FAPa-activated doxorubicin that is in Phase I clinical trial for treating locally advanced or metastatic-selected solid tumors; AVA3996, a tumor-targeted proteasome inhibitor based on bortezomib; AVA-028-PD-L1 Affimer/ImmunoCytokines; AVA-021 - PD-L1 Affimer/LAG-3 Affimer; and TMAC platform that utilizes the proprietary pre|CISION substrate to provide for the selective release of a drug moiety by FAPa. The company has a collaboration agreement with LG Chem for developing and commercializing LR19128 PD-L1 XT; and collaboration and license agreement with Avacta and Daewoong Pharmaceutical Co. Ltd. for developing AFX-001 for solid organ transplant and graft vs host Disease, and AFX-002 for multiple sclerosis. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.
www.avacta.comRecent News: AVCT.L
Performance Overview: AVCT.L
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AVCT.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AVCT.L
Valuation Measures
Market Cap
168.25M
Enterprise Value
164.63M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.92
Price/Book (mrq)
7.40
Enterprise Value/Revenue
10.27
Enterprise Value/EBITDA
-5.18
Financial Highlights
Profitability and Income Statement
Profit Margin
-267.00%
Return on Assets (ttm)
-26.00%
Return on Equity (ttm)
-143.33%
Revenue (ttm)
16.02M
Net Income Avi to Common (ttm)
-42.08M
Diluted EPS (ttm)
-0.16
Balance Sheet and Cash Flow
Total Cash (mrq)
25.97M
Total Debt/Equity (mrq)
225.41%
Levered Free Cash Flow (ttm)
-12.11M